Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
NCT07216742 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this multicenter, randomized, placebo-controlled, double-blind clinical trial is toto evaluate the efficacy and safety of a human menopausal gonadotropin (hMG) in the development of multiple follicles, pregnancy, and cumulative live birth as part of an Assisted Reproductive Technology (ART) cycle in in women with a diagnosis of infertility.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG hMG subcutaneous injection
Study Locations (16)
Florida
- IVF Florida Reproductive Associates — Margate
- Center for Reproductive Medicine — Winter Park
North Carolina
- Reach Fertility — Charlotte
- Carolina Conceptions — Raleigh
Texas
- CARE Fertility — Bedford
- Shady Grove Houston — Webster
California
- HRC Fertility — Encino
Connecticut
- Illume Fertility — Norwalk
Delaware
- Reproductive Associates of Delaware CCRM — Newark
Georgia
- Reproductive Biology Associates (RBA) — Atlanta
Hawaii
- Fertility Institute of Hawaii — Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 659 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2028-11 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216742
The ClinicalTrials.gov registry entry for NCT07216742 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 659 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Granata Bio Corporation, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Infertility (IVF Patients) appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07216742 reports 16 study locations spanning 13 distinct geographic areas — top geographies include Florida, North Carolina, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07216742 about?
NCT07216742 is a clinical study titled "Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.". The goal of this multicenter, randomized, placebo-controlled, double-blind clinical trial is toto evaluate the efficacy and safety of a human menopausal gonadotropin (hMG) in the development of multiple follicles, pregnancy, and cumulative live birth as part of an Assisted Reproductive Technology (A...
What is the current status of trial NCT07216742?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 659 participants. The study started on 2025-11-01. Estimated completion is 2028-11.
What conditions does trial NCT07216742 study?
This clinical trial studies the following conditions: Infertility (IVF Patients). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07216742?
The interventions under investigation include: Placebo (DRUG), hMG subcutaneous injection (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07216742?
This trial is sponsored by Granata Bio Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07216742 being conducted?
This trial has 16 study locations across California, Connecticut, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.